GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Quality Rank

Oncolytics Biotech (Oncolytics Biotech) Quality Rank


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Oncolytics Biotech Quality Rank Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.